The US Food and Drug Administration (FDA) has granted a qualified infectious disease product (QIDP) designation to Aridis Pharmaceuticals’ IgG1 monoclonal antibody (mAb) AR-301.

AR-301 is in a Phase III trial evaluating its safety and efficacy as adjunctive therapy for ventilator-associated pneumonia.

Ventilator-associated pneumonia is one of the most common intensive care unit (ICU)-acquired infections in hospitalised patients receiving mechanical ventilatory support.

AR-301 (tosatoxumab) is a fully human IgG1 mAb that targets the S. aureus alpha-toxin. S. aureus is one of the bacteria that cause ventilator-associated pneumonia.

In a press release, Aridis CEO Vu Truong said: “To our knowledge, AR-301 is the very first antibacterial biologic to be awarded the QIDP designation, marking a significant milestone not only for Aridis but also for companies with biologic solutions to fighting antimicrobial resistance.

“Our AR-301 programme will now benefit from the FDA’s priority review, in addition to previously awarded fast-track status, allowing for accelerated drug development and regulatory review processes.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In May 2023, Aridis received positive feedback from the FDA regarding the expansion of the randomised, placebo-controlled Phase III trial (NCT03816956) to include patients with ventilated hospital-acquired pneumonia and ventilated community-acquired pneumonia. The resulting study will support Aridis’ biologics license application with the FDA.

The tosatoxumab’s Phase III trial was initially delayed due to the Russia-Ukraine conflict, as enrolment was paused in the trial’s sites in the two countries.

As per GlobalData’s analysis, Aridis is expected to be an emerging player in the ventilator-associated pneumonia field with one late-stage and two mid-stage products currently in development, with forecasted sales of $188m in 2029 for tosatoxumab alone.

GlobalData is the parent company of Pharmaceutical Technology.